PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
December 11, 2025European journal of medical research0 citationsOpen Access

Effectiveness and safety of orelabrutinib combined with rituximab, temozolomide, methotrexate, and cytarabine in intensive chemotherapy-unfit patients with PCNSL in China

View Full Paper
ZFZhigang FangFHFenfen HeJGJin Gong

Key Points

  • Evaluate the effectiveness and safety of orelabrutinib combined with other agents in PCNSL patients unfit for intensive chemotherapy.
  • Retrospective study design
  • Involved patients with primary CNS lymphoma
  • Combination of orelabrutinib, rituximab, temozolomide, methotrexate, and cytarabine
  • The ORT-M/A regimen was efficacious
  • The treatment was well-tolerated by patients
  • Provides a potential therapeutic strategy for unfit PCNSL patients

Abstract

The ORT-M/A chemotherapy regimen was efficacious and well-tolerated in our patients with PCNSL. This retrospective study provided a potential therapeutic strategy for PCNSL patients who are unfit for intensive chemotherapy and warrant further investigation.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Fang et al. (2025) studied this question.

synapsesocial.com/papers/69401b172d562116f28f72f5https://doi.org/10.1186/s40001-025-03657-2
Ask AI
Helpful
Bookmark
Share
View Full Paper